• 1. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 2. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Research Brief on (2S)-4-(1,3-dimethyl-1H-pyrazol-4-yl)butan-2-amine (CAS: 2227843-99-2): Recent Advances and Applications

The compound (2S)-4-(1,3-dimethyl-1H-pyrazol-4-yl)butan-2-amine (CAS: 2227843-99-2) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This chiral amine, characterized by a pyrazole moiety, has been investigated for its role as a key intermediate or active pharmaceutical ingredient (API) in the development of novel drugs targeting central nervous system (CNS) disorders, inflammation, and metabolic diseases. Recent studies have highlighted its unique pharmacophore properties, which enable selective interactions with biological targets such as G protein-coupled receptors (GPCRs) and enzymes.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the synthesis and optimization of (2S)-4-(1,3-dimethyl-1H-pyrazol-4-yl)butan-2-amine derivatives to enhance their blood-brain barrier (BBB) permeability and metabolic stability. The study employed a combination of asymmetric synthesis and computational modeling to identify stereospecific interactions critical for binding affinity. Results demonstrated that the (S)-enantiomer exhibited superior pharmacokinetic profiles compared to its (R)-counterpart, with a 2.5-fold increase in bioavailability in rodent models. These findings underscore the importance of chirality in the design of CNS-targeting therapeutics.

Another groundbreaking application of this compound was reported in Nature Chemical Biology, where it served as a scaffold for developing allosteric modulators of the serotonin 5-HT_2C receptor. The study utilized high-throughput screening and structure-activity relationship (SAR) analysis to identify derivatives with nanomolar potency and minimal off-target effects. Notably, the lead compound (derived from 2227843-99-2) showed promise in preclinical models of obesity and schizophrenia, achieving >60% receptor occupancy at low doses without inducing adverse effects commonly associated with orthosteric agonists.

From a mechanistic perspective, the pyrazole ring in (2S)-4-(1,3-dimethyl-1H-pyrazol-4-yl)butan-2-amine has been shown to participate in critical hydrogen-bonding networks with target proteins, as revealed by X-ray crystallography studies. This feature, combined with the compound's conformational rigidity, makes it an attractive template for fragment-based drug discovery (FBDD). Recent patent filings (e.g., WO2023018762) highlight its incorporation into PROTACs (proteolysis-targeting chimeras) aimed at degrading disease-relevant proteins such as tau aggregates in neurodegenerative disorders.

Despite these advances, challenges remain in scaling up the synthesis of this compound while maintaining enantiomeric purity. A 2024 ACS Catalysis paper addressed this issue by developing a biocatalytic route using engineered aminotransferases, achieving >99% ee and reducing waste generation by 70% compared to traditional chemical methods. This sustainable approach aligns with the pharmaceutical industry's growing emphasis on green chemistry principles.

Looking ahead, the versatility of (2S)-4-(1,3-dimethyl-1H-pyrazol-4-yl)butan-2-amine positions it as a valuable building block for next-generation therapeutics. Ongoing clinical trials (NCT05678984) are evaluating its derivatives for treating resistant depression, with preliminary Phase Ib data showing favorable safety profiles. As research continues to unravel its full potential, this compound exemplifies how strategic modifications of small-molecule scaffolds can yield diverse pharmacological activities with clinical relevance.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)